Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Shares of Vertex Pharmaceuticals (NASDAQ: ... (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. ... The smart guide to bill consolidation. Food. Food.

Vertex Pharmaceuticals' current lineup can treat up to 90% of the 83,000 CF patients in North America, Europe, and Australia. Yet, only 50% of this patient population is being treated.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, ... Importantly, suzetrigine met key FDA guidelines for non-opioid analgesics, ...